Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study — Stella

Recruiting

Back to Esophageal Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an, Shannxi

Key details

Phase

Safety & dosing

Sponsor

Tang-Du Hospital

Enrollment target

~80 participants

Started

October 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov